Radiolabeled nanomaterials for biomedical applications: radiopharmacy in the era of nanotechnology
Background Recent advances in nanotechnology have offered new hope for cancer
detection, prevention, and treatment. Nanomedicine, a term for the application of …
detection, prevention, and treatment. Nanomedicine, a term for the application of …
Radiopharmaceutical treatments for cancer therapy, radionuclides characteristics, applications, and challenges
S Salih, A Alkatheeri, W Alomaim, A Elliyanti - Molecules, 2022 - mdpi.com
Advances in the field of molecular biology have had an impact on biomedical applications,
which provide greater hope for both imaging and therapeutics. Work has been intensified on …
which provide greater hope for both imaging and therapeutics. Work has been intensified on …
Efficacy and Safety of 225Ac-PSMA-617-Targeted Alpha Therapy in Metastatic Castration-Resistant Prostate Cancer: A Systematic Review and Meta-Analysis
J Ma, L Li, T Liao, W Gong, C Zhang - Frontiers in Oncology, 2022 - frontiersin.org
Objective To conduct a meta-analysis of the efficacy and safety of 225Ac-PSMA-617 in the
treatment of metastatic castration-resistant prostate cancer based on existing clinical …
treatment of metastatic castration-resistant prostate cancer based on existing clinical …
Radiotheranostics global market and future developments
Radiotheranostics, a combination of diagnostic and therapeutic approaches, was first
utilized in cancer management using radiopharmaceuticals to both image and selectively …
utilized in cancer management using radiopharmaceuticals to both image and selectively …
PSMA theranostics: science and practice
Simple Summary A significant number of prostate cancer patients will progress to metastatic
castrate resistant prostate cancer despite optimal therapies. There is a growing need for …
castrate resistant prostate cancer despite optimal therapies. There is a growing need for …
CD46 targeted 212Pb alpha particle radioimmunotherapy for prostate cancer treatment
We recently identified CD46 as a novel prostate cancer cell surface antigen that shows
lineage independent expression in both adenocarcinoma and small cell neuroendocrine …
lineage independent expression in both adenocarcinoma and small cell neuroendocrine …
Emerging role of nuclear medicine in prostate cancer: current state and future perspectives
Simple Summary The huge armamentarium of currently available theragnostic modalities
allows a novel approach to prostate cancer from imaging to therapy. Clinical examination is …
allows a novel approach to prostate cancer from imaging to therapy. Clinical examination is …
Dosimetry in radiopharmaceutical therapy
J O'Donoghue, P Zanzonico, J Humm… - Journal of Nuclear …, 2022 - Soc Nuclear Med
The application of radiopharmaceutical therapy for the treatment of certain diseases is well
established, and the field is expanding. New therapeutic radiopharmaceuticals have been …
established, and the field is expanding. New therapeutic radiopharmaceuticals have been …
Towards Improving the Efficacy of PSMA-Targeting Radionuclide Therapy for Late-Stage Prostate Cancer—Combination Strategies
D Arbuznikova, M Eder, AL Grosu, PT Meyer… - Current Oncology …, 2023 - Springer
Abstract Purpose of Review [177Lu] Lu-PSMA-617 is a radiopharmaceutical that emits beta-
minus radiation and targets prostate-specific membrane antigen (PSMA)-positive prostate …
minus radiation and targets prostate-specific membrane antigen (PSMA)-positive prostate …
Clinical Experience with [225Ac] Ac-PSMA Treatment in Patients with [177Lu] Lu-PSMA–Refractory Metastatic Castration-Resistant Prostate Cancer
For patients with advanced-stage metastatic castration-resistant prostate cancer (mCRPC)
who do not respond to [177Lu] Lu-PSMA therapy, there are limited treatment options …
who do not respond to [177Lu] Lu-PSMA therapy, there are limited treatment options …